Developing and testing new drugs to treat inflammatory diseases

Developing and testing new drugs to treat inflammatory diseases

Project details

This project focuses on the protein RIP Kinase 2 (RIPK2), which plays an important role in anti-bacterial cell signalling. Recent research also showed that RIPK2 is deregulated in many inflammatory diseases such as Crohn’s disease, multiple sclerosis and rheumatoid arthritis. Therefore RIPK2 has gained the attention as a promising drug target. 

We have previously developed an inhibitor for RIPK2, which was able to block its activity (Nachbur et al; Nat Comms 2015; 6:6442). Based on our previous results, in this project we will now develop new and better drug candidates and test them in a range of biochemical and cellular assays. 

The candidate will use a wide range of techniques to determine the effect of new drugs on RIPK2 and their activity in functional assays for RIPK2.

 

About our research group

We are interested in how RIPK2 contributes to inflammatory diseases and how we can stop the inflammatory processes underlying these diseases by blocking the activity of this kinase. Therefore we have assembled an interdisciplinary team to develop new drugs that have the potential to inhibit RIPK2.

The candidate will work at the interface between chemical biology and cell signalling. As such the candidate will gain important insights into medicinal chemistry and cell biology and contribute to a highly promising project, which has already gained the attention from the pharmaceutical industry. 

 

 

Researchers:

Ueli Nachbur in the lab
Dr
Ueli
Nachbur
Cell Signalling and Cell Death division

Project Type: